ATI0918/NCT01715168.
Trial name or title | A cross‐over bioequivalence study of intravenously administered ATI0918 and DOXIL/CAELYX in patients with ovarian cancer |
Methods | Phase I single‐blind RCT |
Participants | 40 women with ROC |
Interventions | PLD (50 mg/m²) versus ATI‐0918 |
Outcomes | Pharmaco‐equivalence outcomes |
Starting date | Oct 2012 |
Contact information | Karen Kuhn: kkuhn@ockham.com |
Notes | May 2013 |